Teneteplase Reperfusion Therapy in Acute Ischemic Cerebrovascular Events-III

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2022
The trial is a phase 3, multicenter, prospective, randomized, open-label, blinded-endpoint (PROBE) controlled design. Patients with acute ischemic stroke due to anterior circulation large vessel occlusion within 4.5-24 hours from last known well (including wake-up stroke and unwitnessed stroke) will be randomized 1:1 to 0.25mg/kg intravenous tenecteplase or standard medical treatment.
Epistemonikos ID: eec1f8c3c9d76aaf3c17d9f04883f42cfd1fd3e5
First added on: May 09, 2024